Skip to main content

Table 29 Further sensitivity analyses for smoking-adjusted data. Effect of preferring estimates for current smokeless tobacco use to those for ever or unspecified smokeless tobacco use

From: Systematic review of the relation between smokeless tobacco and cancer in Europe and North America

    

Heterogeneity

Cancer

Analysisa

N (nc)b

Random-effects RR/OR (95% CI)

χ2

P

Oropharyngeal

Table 4

19

1.36 (1.04–1.77)

69.5

< 0.001

 

Sensitivity

(5)

1.42 (1.10–1.84)

51.1

< 0.001

Oesophageal

Table 6

7

1.13 (0.95–1.36)

4.4

0.623

 

Sensitivity

(2)

1.11 (0.92–1.34)

4.1

0.665

Stomach

Table 8

8

1.03 (0.88–1.20)

10.3

0.173

 

Sensitivity

(2)

1.01 (0.86–1.19)

10.4

0.165

Pancreatic

Table 10

7

1.07 (0.71–1.60)

21.5

0.001

 

Sensitivity

(2)

1.22 (0.75–2.01)

23.1

< 0.001

Overall digestive

Table 12

5

0.86 (0.59–1.25)

17.3

0.002

 

Sensitivity

(1)

0.85 (0.57–1.27)

17.3

0.002

Larynx

Table 14

2

1.34 (0.61–2.95)

4.0

0.044

 

Sensitivity

(1)

1.45 (0.73–2.88)

2.5

0.116

Lung

Table 16

6

0.99 (0.71–1.37)

28.7

< 0.001

 

Sensitivity

(3)

1.11 (0.73–1.69)

20.6

< 0.001

Prostate

Table 18

4

1.29 (1.07–1.55)

1.2

0.764

 

Sensitivity

(0)

   

Bladder

Table 20

10

0.95 (0.71–1.29)

22.3

0.008

 

Sensitivity

(1)

0.94 (0.68–1.29)

23.7

0.005

Kidney

Table 22

5

1.09 (0.69–1.71)

6.9

0.142

 

Sensitivity

(1)

1.07 (0.60–1.91)

9.6

0.048

Non-Hodgkin's lymphoma

Table 24

3

1.35 (0.62–2.94)

9.5

0.009

 

Sensitivity

(0)

   

Overall

Table 27

7

0.98 (0.84–1.15)

27.1

< 0.001

 

Sensitivity

(1)

0.99 (0.83–1.17)

27.9

< 0.001

  1. a For each cancer the first line repeats the original results preferring ever or unspecified ST use shown in the Table indicated, while the second line presents the results of the sensitivity analysis preferring current ST use.
  2. b N is the number of estimates included in the original and sensitivity analyses; nc is the number of changed estimates. For each cancer, the identification numbers for the estimates (shown in the Table indicated) included in the sensitivity analysis are shown below, with those not used in the original analysis in italic.
  3. Oropharyngeal (Table 3): 2, 3, 4, 8, 11, 13, 18, 26, 35, 43, 48, 51, 55, 56, 58, 61, 70, 74, 75
  4. Oesophageal (Table 5): 3, 6, 10, 11, 19, 20, 23
  5. Stomach (Table 7): 1, 4, 7, 10, 14, 17, 19, 21
  6. Pancreatic (Table 9): 1, 3, 8, 11, 16, 18, 23
  7. Overall digestive (Table 11): 4, 5, 6, 7, 19
  8. Larynx (Table 13): 3, 14
  9. Lung (Table 15): 2, 3, 4, 9, 14, 20
  10. Prostate (Table 17): 1, 3, 5, 7
  11. Bladder (Table 19): 1, 4, 8, 9, 12, 17, 21, 22, 27, 31
  12. Kidney (Table 21): 1, 5, 13, 17, 19
  13. Non-Hodgkin's lymphoma (Table 23): 5, 13, 19
  14. Overall cancer (Table 26): 1, 2, 3, 4, 9, 10, 12
  15. CI = confidence interval; OR = odds ratio; RR = relative risk.
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us